Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Adverse events were mostly mild and resolved spontaneously.

Numinus Announces Clinical Trial Of Psilocybin-Assisted Psychotherapy

Cannabis Life Network

announced early this morning that it will undertake a clinical trial of psilocybin-assisted psychotherapy. About the Research & Clinical Trial Numinus Wellness […]. Vancouver based Numinus Wellness Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

Tryp Therapeutics Announces Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Cannabis Law Report

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The Principal Investigator for the trial will be Kevin Boehnke, Ph.D.,

MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine

Cannabis Law Report

Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc.

FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial

Cannabis Law Report

Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “ Company ” or “ FSD ”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide (“PEA”), or FSD-201, for use in treating COVID-19.

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin.

Recent Study Suggests MMJ Cards Increase the Risk of CUD—But Is There More to It?

Veriheal

The outcomes and measures used throughout the trial included changes in CUD symptoms; anxiety and depressive symptoms; pain severity; and insomnia symptoms. Clinical Trial Sample Size.

RYAH Medtech Inc. Completes Initial Shipment for Major UK-based Clinical Trial

Cannabis Law Report

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain.

Radicle Science Makes History Again With First Large-Scale Clinical Trials on Rare Cannabinoids, Including THCV, CBN, CBG, and CBC

Cannabis Law Report

Radicle Science launches several blinded placebo-controlled clinical trials on rare cannabinoids with 10,000 participants in the first half of 2022 on the heels of completing 25 large-scale CBD studies in 2021.

Clinical Trial on Alzheimer’s Patients Indicates Positive Safety and Tolerability Data for IGC’s THC-Based Investigational New Drug

Cannabis Law Report

IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. POTOMAC, Md.–(BUSINESS

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission

Cannabis Law Report

We are pleased to announce the successful dosing of more than half of the subjects in Part A of our ongoing Phase 2 clinical trial, a study designed to evaluate the safety and effectiveness of ANEB-001 in treating ACI,” said Simon Allen, Chief Executive Officer of Anebulo.

MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Cannabis Law Report

Efficacy data from fully funded Phase 2 trial is expected in first half of 2022. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control tumor necrosis factor-alpha (TNF-?),

Press Release: Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Cannabis Law Report

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs.

MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Cannabis Law Report

Efficacy data from fully funded Phase 2 trial is expected in first half of 2022. The primary endpoint for the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of (TNF-?),

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

Key objective of the trial is to reduce levels of the protein that causes inflammation and activates aging, TNF-?, The primary goal of this Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the levels of tumor necrosis factor-alpha (TNF-?)

Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee

Cannabis Law Report

Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., First Patient Expected to be Enrolled by Q2 of 2022.

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

Puff Puff Post

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. ” “This is a significant milestone for the Company as we transition from a preclinical to a clinical stage organization,” says Eric A.

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

VANCOUVER, March 10, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV).

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

Puff Puff Post

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. ” “This is a significant milestone for the Company as we transition from a preclinical to a clinical stage organization,” says Eric A.

iCann Goes Psychedelic With Tel Aviv PsyTech Summit Global Event

Cannabis Law Report

With our recent event in Cape Town, we have now brought CannaTech to every continent and helped build the cannabis footprint across the world. The first PsyTech Summit Global Event will take place in Tel Aviv on March 29-30, 2020. Here’s the press release we received this morning.

Answer of the Day for Nov 30, 2021

TheAnswerPage

What serious adverse events have been noted in psilocybin clinical trials?

Answer of the Day for Mar 12, 2022

TheAnswerPage

In the clinical trials evaluating a purified CBD product (Epidiolex) in epilepsy patients, side effects including sedation, decreased appetite, diarrhea, sleep disturbance, infections, pneumonia, viral infections and weight loss were reported.

Study: Potential Adverse Drug Events When Combining THC with Other Medication

The Joint Blog

According to a new study in the Journal of Clinic Medicine , the use of Tetrahydrocannabinol (THC) could have adverse drug effects when combined with other medications due to drug-drug interactions.

Answer of the Day for Feb 24, 2022

TheAnswerPage

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). Some of these studies have shown positive results, but adverse events were also noted.

FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

Cannabis Law Report

Combined with our existing cash on hand, we are sufficiently capitalized for operations through 2025, inclusive of budget allocations for planned clinical trials and without having to look to the capital markets for any additional funds. Nets CAD$15,480,780 cash in non-dilutive capital.

Flora Growth Acquires CBD Brand Masaya

Cannabis Law Report

In addition, it is expected that the original patent-pending formulation, Masaya Pure , will be used in Flora’s current clinical trials with the University of Manchester in the UK. FORT LAUDERDALE, Fla. & & TORONTO–(BUSINESS WIRE)–Flora Growth Corp.

Fragile X Syndrome Market Spotlight Report 2021: 10-year Disease Incidence and Prevalence Forecasts, Probability of Success, Licensing and Asset Acquisition Deals, Drug-specific Revenue Forecasts – ResearchAndMarkets.com

Cannabis Law Report

The majority of industry-sponsored drugs in active clinical development for FXS are in Phase II, with two drugs in Phase III. The US has a substantial lead in the number of FXS clinical trials globally. Clinical trial activity in the FXS space is dominated by completed trials.

What A Surprise …Not. “TGA blocks bid to have MDMA, magic mushrooms used to treat mental health conditions”

Cannabis Law Report

A number of clinical trials have been investigating the potential of psychedelics in mental health treatment. The psychedelic drug trial for terminally ill patients that’s brought researchers to tears. The ABC (Australia) reports.

Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation

Cannabis Law Report

Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Primary endpoint showed a median 16.6%

FSD Pharma Announces Agreement for Sale of Cobourg Facility for CAD$16,500,000

Cannabis Law Report

Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. TORONTO–(BUSINESS WIRE)– $HUGE #FSDPharma –FSD Pharma Inc.

Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

Cannabis Law Report

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), today announced the appointment of Dr. Kenneth Cundy, Ph.D.

Press Release: PsyBio Therapeutics Furthers Intellectual Property Portfolio with Six New Manufacturing Patent Applications

Cannabis Law Report

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application

Cannabis Law Report

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. Subject to the approval of Health Canada, the licence will effectively enable KGK to offer a turn-key solution for third parties to conduct clinical trials involving psychedelic molecules, while also authorizing KGK to act as a centralized distributor for large, multi-location clinical trials.

Psymposia Report: MAPS Canada’s Data Breach Foreshadows Corporadelic Future

Cannabis Law Report

Psymposia report… O n Sep 23, 2021, Psymposia staff received an email from the personal email account of Mark Haden — the former Executive Director of psychedelic nonprofit MAPS Canada and current Director of Clinical Trials for Psygen Inc.

Data 52

MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15

Cannabis Law Report

Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. Investors may register for the conference at the event website. The live and archived webcast will be available for 90 days after the event.

Cybin Announces Closing of Overnight Marketed Public Offering of Common Shares and Exercise of Over-Allotment Option

Cannabis Law Report

Actual results and future events could differ materially from those anticipated in such information. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products.